Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) EBT Margin (2016 - 2025)

Standard Biotools (LAB) has disclosed EBT Margin for 16 consecutive years, with 3227.03% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin rose 201654.0% to 3227.03% in Q3 2025 year-over-year; TTM through Sep 2025 was 84.41%, a 1498.0% decrease, with the full-year FY2024 number at 79.29%, down 4113.0% from a year prior.
  • EBT Margin was 3227.03% for Q3 2025 at Standard Biotools, up from 84.01% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 3227.03% in Q3 2025 to a low of 346.98% in Q2 2022.
  • A 5-year average of 183.54% and a median of 62.49% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: plummeted -51868bps in 2023, then soared 201654bps in 2025.
  • Standard Biotools' EBT Margin stood at 26.77% in 2021, then skyrocketed by 2219bps to 567.21% in 2022, then tumbled by -91bps to 48.53% in 2023, then tumbled by -213bps to 54.6% in 2024, then skyrocketed by 6010bps to 3227.03% in 2025.
  • Per Business Quant, the three most recent readings for LAB's EBT Margin are 3227.03% (Q3 2025), 84.01% (Q2 2025), and 80.82% (Q1 2025).